#1 Clinical Trials Search in Europe

Pegvaliase

Pegvaliase, also known as Palynziq, is a promising drug being studied in clinical trials for the treatment of phenylketonuria (PKU). PKU is a genetic disorder that affects the body’s ability to break down the amino acid phenylalanine. These trials aim to evaluate the safety, efficacy, and long-term effects of pegvaliase in various patient populations, including adults, adolescents, and pregnant women with PKU. The studies also explore the drug’s impact on nutritional status, brain function, and quality of life for individuals living with this condition.

Table of Contents

What is Pegvaliase?

Pegvaliase, also known by its brand name Palynziq®, is a medication used to treat adults with a rare genetic disorder called phenylketonuria (PKU). Other names for pegvaliase include rAvPAL-PEG, PEG PAL, and BMN 165[1][6]. PKU is a condition where the body cannot properly break down an amino acid called phenylalanine (Phe), which is found in many foods containing protein. As a result, Phe builds up in the blood and can cause serious health problems if left untreated.

How Pegvaliase Works

Pegvaliase is an enzyme therapy that helps break down Phe in the blood. It works by replacing the enzyme that people with PKU are missing or have in low amounts. By reducing Phe levels in the blood, pegvaliase aims to prevent the harmful effects of high Phe concentrations on the body, especially the brain[1].

Treatment for Phenylketonuria (PKU)

Pegvaliase is specifically designed to treat PKU in adults. It’s used when other treatments, such as a strict low-protein diet, haven’t been effective in lowering blood Phe levels. The goal of treatment is to reduce blood Phe concentrations to below 360 µmol/L (micromoles per liter), which is considered a safe level for adults with PKU[7].

Dosage and Administration

Pegvaliase is administered as a subcutaneous injection, which means it’s injected just under the skin. The dosage can range from 2.5 mg to 60 mg per day, depending on the individual patient’s needs and response to treatment. Patients typically start with a lower dose, which is gradually increased over time to reach the most effective dose[6].

Safety and Efficacy

Clinical trials have shown that pegvaliase can effectively lower blood Phe levels in many adults with PKU. However, like all medications, it can cause side effects. The most common side effects include injection site reactions and allergic reactions. In some cases, more severe allergic reactions can occur, which is why patients are closely monitored when starting treatment[1][4].

Some of the safety concerns that doctors watch for include:

  • Acute systemic hypersensitivity reactions: These are sudden allergic reactions that affect the whole body.
  • Anaphylaxis: A severe, potentially life-threatening allergic reaction.
  • Angioedema: Swelling under the skin, often around the face and throat.
  • Serum sickness: A delayed type of allergic reaction that can cause fever, joint pain, and rash.
  • Severe injection site reactions: Significant pain, swelling, or other problems at the injection site.
  • Arthralgia: Joint pain that can be severe or long-lasting (persistent).

Long-Term Studies

Several long-term studies are currently underway to further evaluate the safety and effectiveness of pegvaliase. These studies aim to gather information about the medication’s effects over extended periods, some lasting up to 10 years. They will help researchers better understand how pegvaliase affects patients over time and identify any potential long-term side effects[5][4].

Special Populations

While pegvaliase is currently approved for use in adults, research is ongoing to determine its safety and effectiveness in other groups:

  • Adolescents: Studies are being conducted to evaluate pegvaliase in patients aged 12-17 years old[6].
  • Pregnant and breastfeeding women: Research is being done to assess the safety of pegvaliase during pregnancy and breastfeeding[2].

Nutritional Considerations

One important aspect of pegvaliase treatment is its effect on nutrition. As the medication lowers Phe levels, patients may be able to increase their protein intake. Studies are being conducted to evaluate the nutritional status of adults treated with pegvaliase, including their protein intake and overall diet quality. This information will help healthcare providers better manage the nutritional needs of patients on pegvaliase[3].

Neurological Effects

Researchers are also investigating how pegvaliase-related reductions in blood Phe levels affect the brain. Studies are using advanced brain imaging techniques and cognitive tests to examine changes in brain structure, function, and cognitive performance in patients treated with pegvaliase. This research may help us understand how lowering Phe levels can improve brain health and cognitive function in people with PKU[7].

Aspect Details
Drug Name Pegvaliase (Palynziq)
Condition Treated Phenylketonuria (PKU)
Study Populations Adults, adolescents (12-17 years), pregnant women with PKU
Primary Outcomes Blood phenylalanine reduction, safety profile, adverse events
Secondary Outcomes Nutritional status, brain effects, pregnancy outcomes, long-term safety
Study Durations Ranging from 1 year to 10 years
Key Safety Monitoring Hypersensitivity reactions, immune responses, organ function
Unique Aspects Pregnancy exposure study, brain imaging research, long-term observational studies

FAQ

  • What is pegvaliase and how does it work for PKU? Pegvaliase is an enzyme therapy designed to break down phenylalanine in the blood of people with PKU. It helps lower phenylalanine levels, potentially allowing patients to have a less restricted diet and improve their overall health.
  • Who is being studied in these clinical trials? The trials include various groups: adults with PKU, adolescents aged 12-17, pregnant women with PKU, and their infants exposed to pegvaliase during pregnancy or breastfeeding.
  • What are the main goals of these clinical trials? The trials aim to assess the safety and efficacy of pegvaliase, evaluate long-term effects, study its impact on nutrition and brain function, and monitor outcomes in pregnant women and their babies.
  • Are there any specific safety concerns being monitored? Yes, the trials are closely monitoring for adverse events, particularly hypersensitivity reactions, immune responses, and any effects on organ function. They're also tracking long-term safety and tolerability.
  • How long do these clinical trials last? The duration varies, with some trials lasting up to 10 years to gather comprehensive long-term data on pegvaliase use in PKU patients.

Ongoing Clinical Trials on Pegvaliase

  • Study of pegvaliase injections compared to diet control in adolescents aged 12-17 with phenylketonuria (PKU)

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Germany

Glossary

  • Phenylketonuria (PKU): A genetic disorder that affects the body's ability to break down the amino acid phenylalanine, leading to its buildup in the blood and potentially causing serious health problems if left untreated.
  • Pegvaliase: An enzyme therapy drug designed to break down phenylalanine in the blood of people with PKU. It's also known by the brand name Palynziq.
  • Phenylalanine (Phe): An essential amino acid that people with PKU have difficulty metabolizing. High levels can be toxic to the brain and nervous system.
  • Hypophenylalaninemia: A condition where phenylalanine levels in the blood are abnormally low, which can be a side effect of PKU treatment.
  • Anaphylaxis: A severe, potentially life-threatening allergic reaction that can occur rapidly after exposure to an allergen.
  • Angioedema: Swelling under the skin, often occurring in the face, throat, or extremities, which can be a sign of an allergic reaction.
  • Serum sickness: A type of delayed immune reaction that can cause symptoms such as fever, joint pain, and rash.
  • Arthralgia: Joint pain, which can be a side effect of some medications or treatments.
  • Ecological momentary assessment (EMA): A research method that involves repeatedly sampling participants' behaviors and experiences in real time, in their natural environments.
  • Magnetic resonance spectroscopy (MRS): A non-invasive imaging technique used to measure the concentrations of different metabolites in the brain and other tissues.

References

  1. https://clinicaltrials.gov/study/NCT03694353
  2. https://clinicaltrials.gov/study/NCT05579548
  3. https://clinicaltrials.gov/study/NCT03792451
  4. https://clinicaltrials.gov/study/NCT06305234
  5. https://clinicaltrials.gov/study/NCT05813678
  6. https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-pegvaliase-for-adolescents-aged-12-17-with-phenylketonuria-pku/
  7. https://clinicaltrials.gov/study/NCT05356377